A preclinical study showed reduced tumor growth and increased immune cell infiltration in a mouse model of prostate cancer with IL-15 overexpression 2.5-fold and 2.7-fold higher numbers of CD8+ T cells and NK cells, respectively than in mice in the model without IL-15 injection (Morris et al., 2014). This evidence concerns the gene IL15 and prostate carcinoma.